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ABSTRACT
Objectives: Spironolactone and furosemide are diuretics used to treat liver cirrhosis with ascites, but not case studies have been found to distinguish 
the effects of spironolactone and its combination with furosemide in cases of cirrhosis accompanied by ascites. This study aims to determine the 
effectiveness of spironolactone therapy and its combination with furosemide to liver cirrhosis patients accompanied ascites.
Methods: This research was done by cross-sectional prospective method. 26 patients staying at RSUP H.  Adam Malik Medan For 3 months were divided into 2 
groups. The first group of nine patients, age between 39 and 65 years, was given spironolactone. The second group of 17 patients, age between 20 and 81 years, 
was given spironolactone combined with furosemide. The sample data were analyzed with statistics using Mann–Whitney U-test, SPSS program version 22.
Result: Based on Mann–Whitney U statistic test, the value of p value. Significance (2-tailed) 0.435 for urine Na/K at time, and Asymp. significance value 
(2-tailed) 0.628 24 h urine sodium examination, based on the value, it was concluded that there was no significant difference between spironolactone 
with its combination with furosemide. Even though the significant value was 0.628 mEq and 0.435 mEq (p>0.05).
Conclusion: This study showed that the combination of spironolactone with furosemide was better than compared to spironolactone. Moreover, there 
was no statistically significant difference compared with 24 hours of urine sodium value with a normal value of 78 mEq.
Keywords: Cirrhosis, Ascites, Spironolactone, Its combinations with furosemide.
INTRODUCTION
Liver cirrhosis is the ultimate pathology of various liver diseases [1]. 
The term cirrhosis was first introduced by Laennec in 1826. Cirrhosis 
of the liver comes from the Greek word scirrhus or shows the orange 
or brownish-yellow color of the surface of the liver seen at autopsy. 
Many forms of liver damage are characterized by fibrosis. Fibrosis is 
an excessive buildup of extracellular matrix in the liver. The fibrosis 
response to liver damage is reversible. However, in most patients with 
liver cirrhosis, the fibrosis process is not reversible [2].
According to the World Health Organization, in 2000, about 170 million 
suffered from liver cirrhosis. This number accounts for about 3% of the 
total human population in the world and every year the incidence of 
new liver cirrhosis increases from 3 to 4 million people. Chronic liver 
disease and liver cirrhosis can cause about 35,000 deaths year in the 
United States. Cirrhosis is the ninth leading cause of death in the United 
States [3,4]. Liver cirrhosis is the most common cause of ascites in the 
United States, accounting for about 85% of cases [5].
The prevalence rate of liver cirrhosis disease in Indonesia is definitely 
not known. However, from several reports of the public hospital in 
Indonesia based on clinical diagnosis, the prevalence of cirrhosis of the 
liver treated in the ward of the disease generally ranges from 3.6% to 
8.4% in Java and Sumatera, while in Sulawesi and Kalimantan below 
1%. Overall, the average prevalence of liver cirrhosis was 3.7% of all 
patients treated in the internal medicine ward or an average of 47.4% 
of all treated liver disease patients [2].
The major complications of liver cirrhosis include ascites, hepatic 
encephalopathy, portal hypertension, variceal hemorrhage, and 
hepatorenal syndrome [6]. Treatment of cirrhosis of the liver and ascites 
begins with salt diet, salt consumption of 5.2 g or 90 mEq/day. Low-salt 
diet combined with diuretics. Initially, it begins with the spironolactone 
dose 100–200 mg once a day. The diuretic response was monitored 
with 0.5 kg/day weight loss, without foot, or 1 kg/day edema with 
edema of the foot. Or inadequate spironolactone administration can be 
combined with furosemide at a dose of 20-40 mg/day. Administration of 
furosemide dosage may be increased if there is no response; maximum 
dose of 160 mg/day [7].
METHODS
Research design
This study was conducted with a prospective cross-sectional study 
design on spironolactone and its combination with furosemide at RSUP 
H. Adam Malik Medan, using urine Na/K examination and 24-h urine 
sodium. The study was analyzed statistically using Mann–Whitney 
U-test, SPSS Statistic program version 22.
Data source
The research sources were medical records of liver cirrhosis patients 
with accompanying ascites receiving SIRS (hospital information 
system) records of nurses in inpatient rooms, patient interview records, 
and clinical pathology laboratory examinations.
Time of study
The study was conducted in the hospitalization of Rindu A, Rindu B, and 
RIC in RSUP H. Adam Malik Medan.
Population and sample
Population
The population in this study was all patients with liver cirrhosis 
accompanied by ascites in the hospitalization of Rindu A, Rindu B, and 
RIC in RSUP H. Adam Malik Medan.
Sample
The samples in this study were populations that met the inclusion 
criteria and did not meet the exclusion criteria.
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The inclusion criteria are
Inclusion criteria
a. Patients with cirrhosis of the liver accompanied by ascites who 
are hospitalized internal wards integrated diagnostic installation 
diagnosed by anamnesis, physical examination and laboratory, and 
diuretic therapy received at least 1 day
b. Willing to be the object of research by signing informed consent
c. The type of diuretic used in the treatment of spironolactone and its 
combination with furosemide.
Exclusion criteria
Patients who are not allowed to participate in this study, if they have:
a. Kidney abnormalities, as evidenced by serum creatinine <1.5 mg/
dL
b. Refused to participate
c. Not using spironolactone
d. Does not use the combination with furosemide.
Number of samples
The sample size was the number of liver cirrhosis patients with 
inpatient ascites receiving spironolactone therapy and its combination 
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The steps of this research are carried out as follows:
a. The research was conducted after obtaining informed consent, 
approved	by	Ethical	Research	Commission	of	health	field	of	Faculty	
of Medicine, University of Sumatera Utara, and got approval from 
the director of RSUP H. Adam Malik Medan.
b. Data collection of all spironolactone therapy and its combination with 
furosemide given in liver cirrhosis patients with ascites of inpatient 
based on Formulary of RSUP H. Adam Malik Medan, list of Jamkesmas 
diuretic drugs.
c. Choose patients who meet inclusion criteria.
d. Data retrieval.s
Research procedures
The materials examined were 24-h urine sodium and Na/K as collected 
in Gergen (24-h urine sodium) and in the bottle (Na/K urine at a 
time), which were examined by an electrolyte analyzer using the ion 
selective electrode (ISE)  method. Measurement of this tool is using ISE 
or ISE. Where in this tool, there are four pieces of electrode that is Na 
electrode, K electrode, Cl electrode, and reference electrode. Electrolyte 
analyzer can detect inorganic salt ions, small calcium ion material 
samples. The electrolyte working system is when electrolyte ions enter 
the electrode arising electrical potentials proportional to the electrolyte 
ion concentration. Then, the electric potential is corroborated 
and converted through the processor to the value of electrolyte 
concentration. The working principle of this tool that the sample will be 
drawn by electrodes that are sensitive to these ions. Then, a reference 
electrode is used to compare potential ups and downs [9].
The data collected in this research are
a. Records of medical record data at inpatient Rindu A, Rindu B, and 
RIC at RSUP H. Adam Malik Medan include data of demographic 
characteristics of patients (name, gender, age, and ethnicity).
b. Patient data related to each criterion of liver cirrhosis accompanied 
by ascites, drug selection.
c. Patient laboratory data, recorded after diuretic administration. 
Assessment/measurement of urine sodium 24 h.
d. Patient laboratory data, recorded after diuretic administration. 
Assessment/Measurement of urine sodium 24 hours and Na/K 
urine at a time, was done by compared 24-hour urine sodium using 
spironolactone and its combination with furosemide and compared 
with Na/K urine when using spironolactone and its combination with 
furosemide.
e. The captured data were moved to the data collection sheets. Lack of 
medical record data was supplemented by looking at nurse records, 
SIRS data (Hospital Information System), and looking at the patient’s 
condition.
Data analysis
The data obtained are presented in table form, then analyzed statistically 
using Mann–Whitney U-test, SPSS Statistic program version 22.
RESULT AND DISCUSSION
RESULTS
A prospective cross-sectional study was conducted on liver cirrhosis 
patients with ascites using spironolactone and its combination with 
furosemide in the RSUP H. Adam Malik Hospital Medan from June 2017 
to September 2017 with 24-h urine sodium and urine Na/K.
Demographic characteristics of research subjects
Based on the number of samples, there are as many as 26 patients 
with liver cirrhosis accompanied ascites that have met the inclusion; as 
many as 17 patients (65.38%), men aged 20–81 years, while women as 
many as 9 patients (34.61%), with age 30–67 years; mostly from tribe 
of Batak 13 people (50%), Javanese 10 patients (38.46%), and Malay 
3 patients (11.53%). The study was divided into two groups of patients, 
Group I using a single drug (spironolactone) of 9 patients; men 5 people 
(55.55%), while women 4 patients (44.44%); with age 20–81 years, 
Batak 2 (22.22%), Javanese 6 (66.66%), and Malay 1 (11.11%). Group II 
used its combination with furosemide of 17 patients, 12 patients 
(70.58%), 5 (29.41%), age 39–65; Batak tribe 11 (64.70%), Java 
4 (23.52%), and Malay 2 (11.76%).
To determine what statistical tests were used for the spironolactone 
group and its combination with furosemide, the normality test was 
first performed. The test data of normality of Na/K urinecan be seen in 
Table 1, Sodium Urine Value Result When Using Mann-Whitney Test Test 
seen in Table 2, 24-hour urine sodium normality test data can be seen in 
Table 3, and 24-hour Sodium Urine Value Using the Mann-Whitney Test 
Test seen in Table 4.
DISCUSSION
The population of this study was 26 patients, most of the patients 
in RSUP H. Adam Malik Medan were male patients, amounted to 
17 (65.38%) patients, while women were 9 (34.61%) patients. In 
this study, the patients used spironolactone and its combination with 
furosemide, which used spironolactone as many as 9 patients, from 9 
patients were men, 5 patients, women 4 patients aged patients ranged 
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from 39-65 year. While using combination with furosemide as many 
as 17 male patients amounted to 12 patients, women 5 patients with 
age ranged from 20 to 81 years. Overall, there were more male patients 
than women. Liver cirrhosis is a major risk factor for liver cancer in the 
world and underlies more than 80% of cases of liver cancer. Every year 
3–5% of patients with liver cirrhosis will have liver cancer. Moreover, 
liver cancer is one of the causes of death in cirrhosis of the liver; the 
time it takes cirrhosis of the liver to develop into liver cancer is about 
3 years. Alcohol consumption is a risk factor for cirrhosis of the liver. 
Alcohol-heavy drinkers (more than 50–70 g/day and prolonged) are at 
risk for liver cancer through alcoholic liver cirrhosis, the mechanism 
of liver disease due to alcohol consumption is uncertain, liver cells 
undergo prolonged fibrosis and protein destruction due to alcohol 
metabolism that results in acetaldehyde. Fibrosis that occurs stimulates 
the formation collagen. Regeneration of cells still occurs but cannot 
compensate for cell damage. The accumulation of collagen continues, 
the size of the liver narrows, lumps, and hardened resulting in cirrhosis 
of the liver [10].
In liver cirrhosis with ascites, spironolactone response to liver 
cirrhosis patients accompanied ascites, with urine Na/K examination 
with normal values >1 mEq result of good response laboratory value, 
while 24 hours urine suture test 3 patients less responsive to the value 
<78 mEq. Spironolactone is widely used for the treatment of liver 
cirrhosis ascites complications [11]. While the combined response with 
furosemide with urine Na/K examination when the response is good to 
the value >1 mEq. A 24-h urine sodium examination had two patients 
<78 mEq. Based on the results, it was concluded that the combination 
with furosemide was better than spironolactone. Its combination with 
furosemide is widely used for the treatment of liver cirrhosis to enlarge 
diuresis.
After test with Mann–Whitney U statistic test and compared urine Na/K 
examination during spironolactone and Na/K urine during combination 
with furosemide, it was obtained that Asymp. significance (2-tailed) 
0.435 value was statistically no significant difference. Moreover, 24 
h of urinary sodium test against spironolactone compared with its 
combination with furosemide. Asymp. significance (2-tailed) 0.628 
value shows no significant difference between spironolactone and 
its combination with furosemide based on the significance (2-tailed) 
value obtained >0.05, i.e. 0.435 for Na/K urine and 0.628 for 24-h urine 
sodium.
According to [12], the principle of treating liver cirrhosis ascites 
complications is to make the balance of abnormal sodium, one of 
them with the use of diuretics; the use of diuretics in the treatment 
of therapy is done immediately by considering the low efficacy of 
sodium diet restriction. The purpose of diuretic use was to evaluate 
the effectiveness of diuretics on the development of liver cirrhosis 
response to ascitic complications. Previous studies have compared 
spironolactone and its combination with furosemide, which used 
spironolactone 8 patients and used a combination of spironolactone 
with furosemide 27 patients. Administration of diuretics effectively 
decreases ascites in cirrhosis of the liver seen from the circumference 
of the stomach and the patient’s weight. Based on the results statistics 
no significant difference between spironolactone and combination of 
spironolactone with furosemide.
Cirrhosis is a complication of liver disease characterized by the 
disappearance of liver cells and the formation of connective tissue in 
the liver that is irreversible. Alcohol and viral hepatitis B and C are the 
leading cause of liver cirrhosis, although there are many other causes. 
Cirrhosis can cause weakness, loss of appetite, itching, and fatigue. 
Suspected cirrhosis on the basis of anamnesis, physical examination, 
and blood tests, cirrhosis is confirmed by liver biopsy. Complications 
of cirrhosis include edema, ascites, and liver cancer. Treatment of liver 
cirrhosis aims to prevent further liver damage, treat complications, and 
prevent liver cancer. Moreover, liver transplantation is now one of the 
important options for the treatment of advanced liver cirrhosis patients.
CONCLUSION
Based on observations during the study and discussion, it can be 
concluded: The combination of spironolactone with furosemide was 
better than spironolactone although statistically there was no significant 
difference, better laboratory result of spironolactone combination with 
furosemide was seen from the comparison of 24-h urine sodium value 
with normal value of 78 mEq.
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